The European Commission has approved Sarclisa in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The decision is based on a study in which Sarclisa combination therapy reduced the risk of disease progression or death by 47%.